Stryker (SYK) Competitors

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.1% of Cardinal Health shares are owned by company insiders. Comparatively, 4.6% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Stryker had 16 more articles in the media than Cardinal Health. MarketBeat recorded 28 mentions for Stryker and 12 mentions for Cardinal Health. Cardinal Health's average media sentiment score of 1.34 beat Stryker's score of 1.08 indicating that Cardinal Health is being referred to more favorably in the media.

Stryker has lower revenue, but higher earnings than Cardinal Health. Stryker is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Stryker has a net margin of 14.43% compared to Cardinal Health's net margin of 0.67%. Stryker's return on equity of 23.63% beat Cardinal Health's return on equity.

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.9%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.3%. Cardinal Health pays out 28.5% of its earnings in the form of a dividend. Stryker pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years and Stryker has raised its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Cardinal Health has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Stryker has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Cardinal Health currently has a consensus price target of $266.56, indicating a potential upside of 10.91%. Stryker has a consensus price target of $381.40, indicating a potential upside of 39.44%. Given Stryker's higher possible upside, analysts plainly believe Stryker is more favorable than Cardinal Health.

Stryker has a net margin of 14.43% compared to Cencora's net margin of 0.79%. Cencora's return on equity of 125.45% beat Stryker's return on equity.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.3%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.7%. Stryker pays out 36.5% of its earnings in the form of a dividend. Cencora pays out 17.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and Cencora has raised its dividend for 15 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker presently has a consensus target price of $381.40, suggesting a potential upside of 39.44%. Cencora has a consensus target price of $370.85, suggesting a potential upside of 13.83%. Given Stryker's higher possible upside, equities research analysts clearly believe Stryker is more favorable than Cencora.

Stryker has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Cencora has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

In the previous week, Stryker had 2 more articles in the media than Cencora. MarketBeat recorded 28 mentions for Stryker and 26 mentions for Cencora. Cencora's average media sentiment score of 1.09 beat Stryker's score of 1.08 indicating that Cencora is being referred to more favorably in the news media.

77.1% of Stryker shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 0.4% of Cencora shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Stryker has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 1.9% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Stryker had 23 more articles in the media than DaVita. MarketBeat recorded 28 mentions for Stryker and 5 mentions for DaVita. Stryker's average media sentiment score of 1.08 beat DaVita's score of 0.61 indicating that Stryker is being referred to more favorably in the media.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker currently has a consensus target price of $381.40, indicating a potential upside of 39.44%. DaVita has a consensus target price of $221.75, indicating a potential upside of 20.28%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than DaVita.

Stryker has a net margin of 14.43% compared to DaVita's net margin of 6.05%. Stryker's return on equity of 23.63% beat DaVita's return on equity.

Stryker has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, DaVita has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Medtronic has higher revenue and earnings than Stryker. Medtronic is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

In the previous week, Medtronic had 22 more articles in the media than Stryker. MarketBeat recorded 50 mentions for Medtronic and 28 mentions for Stryker. Stryker's average media sentiment score of 1.08 beat Medtronic's score of 0.83 indicating that Stryker is being referred to more favorably in the media.

Stryker presently has a consensus price target of $381.40, suggesting a potential upside of 39.44%. Medtronic has a consensus price target of $103.92, suggesting a potential upside of 12.47%. Given Stryker's stronger consensus rating and higher possible upside, equities analysts clearly believe Stryker is more favorable than Medtronic.

Stryker has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 4.6% of Stryker shares are owned by insiders. Comparatively, 0.3% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.3%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.1%. Stryker pays out 36.5% of its earnings in the form of a dividend. Medtronic pays out 70.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and Medtronic has raised its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has a net margin of 14.43% compared to Medtronic's net margin of 13.93%. Stryker's return on equity of 23.63% beat Medtronic's return on equity.